Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of BKM120 in Subjects With Mild, Moderate and Severe Hepatic Impairmen

NCT01727128 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01727128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01727128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of BKM120 in Subjects With Mild, Moderate and Severe Hepatic Impairmen
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2011
Completion date
August 31, 2013
Enrollment
31 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment